Inflammatory syndrome in chronic kidney disease: Pathogenesis and influence on outcomes

Inflammation and Allergy - Drug Targets

Volumn 8, Issue 5, 2009, Pages 369-382

  Filiopoulos, Vasilis ^a   Vlassopoulos, Dimosthenis ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

C reactive protein (CRP); Cardiovascular disease (CVD); Chronic kidney disease (CKD); Dialysis; Inflammation; Interleukin 6 (IL 6); Morbidity; Mortality

Indexed keywords

ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIURETIC AGENT; ERYTHROPOIETIN; HOMOCYSTEINE; IMMUNOLOGIC FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IRBESARTAN; IRON; VASCULAR CELL ADHESION MOLECULE 1;

ACIDOSIS; ADD ON THERAPY; ANEMIA; ATHEROSCLEROSIS; BACTERIAL INFECTION; BIOCOMPATIBILITY; BLOOD VESSEL CALCIFICATION; BONE MINERAL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; DIABETIC NEPHROPATHY; DIALYSATE; HEART FAILURE; HEMODIALYSIS PATIENT; HEREDITY; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; KNOWLEDGE; MALNUTRITION; MINERAL METABOLISM; MORTALITY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; POPULATION; PREDICTION; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; REVIEW; UREMIA;

EID: 74849118821     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528110908050369     Document Type: Review

References (118)

1. Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 2004, 351, 1296-1305.
2. Rayner, H.C.; Pisoni, R.L.; Bommer, J.; Canaud, B.; Hecking, E.; Locatelli, F.; Piere, L.; Bragg-Gresham, J.L.; Feldman, H.I.; Goodkin, D.A.; Gillespie, B.; Wolfe, R.A.; Held, P.J.; Port, F.K. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant., 2004, 19, 108-20.
3. Berl, T.; Heinrich, W. Kidney-heart interactions: epidemiology, pathogenesis and treatment. Clin. J. Am. Soc. Nephrol., 2006, 1, 8-18.
4. Schiffrin, E.L.; Lipman, M.L.; Mann, J.F.E. Chronic kidney disease. Effects on the cardiovascular system. Circulation, 2007, 116, 85-97.
5. Vlagopoulos, P.T.; Sarnak, M.J. Traditional and non-traditional cardiovascular risk factors in chronic kidney disease. Med. Clin. North. Am., 2005, 89, 587-611.
6. Cheung, A.K.; Sarnak, M.J.; Yan, G.; Berkoben, M.; Heyka, R.; Kaufman, A.; Lewis, J.; Rocco, M.; Toto, R.; Windus, D.; Ornt, D.; Levey, A.S.; HEMO Study Group. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.Kidney Int., 2004, 65, 2380-9.
7. Kendrick, J.; Chonchol, M.B. Non-traditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat. Clin. Pract. Nephrol., 2008, 4, 672-81.
8. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol. Dial. Transplant., 2000, 15, 454-7.
9. Locatelli, F.; Canaud, B.; Eckardt, K.U.; Stenvinkel, P.; Wanner, C.; Zoccali, C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transplant., 2003, 18, 1272-80.
10. Cachofeiro, V.; Goicochea, M.; Garcia, de Vinuesa S.; Oubina, P.; Lahera, V.; Luno, J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int., 2008, 74, 54-9.
11. Kalantar-Zadeh, K.; Ikizler, T.A.; Block, G.; Avram, M.M;., Kopple, J.D. Malnutrition-Inflammation Complex Syndrome in dialysis patients: causes and consequences. Am. J. Kidney Dis., 2003, 42, 864-81.
12. Weiner, D.E.; Tighiouart, H.; Elsayed, E.F.; Griffith, J.L.; Salem, D.N.; Levey, A.S.; Sarnak, M.J. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int., 2008, 73, 1406-12.
13. Blake, G.J.; Ridker, P. Inflammatory biomarkers and cardiovascular risk prediction. J. Intern. Med., 2002, 252, 283-94.
14. Pepys, M.B. C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat. Clin. Pract. Nephrol., 2008, 4, 234-5.
15. Mansunuru, K.; Kral, B.G.; Blumenthal, R.S.; Fuster, V.; Campbell, C.Y.; Gluckman, T.J.; Lange, R.A.; Topol, E.J.; Willerson, J.T.; Desai, M.Y.; Davidson, M.H.; Mora, S. The use of high sensitivity C-reactive protein in clinical practice. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5, 621-35.
16. Liuzzo, G.; Biasucci, L.M.; Gallimore, J.R.; Grillo, R.L.; Rebuzzi, A.G.; Pepys, M.B.; Maseri, A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Eng. J. Med., 1994, 331, 417-24.
17. Stenvinkel, P. Inflammation in end-stage renal disease: could it be treated? Nephrol. Dial. Transplant., 2002, 17, 33-8.
18. Chung, S.H.; Heimburger, O.; Stenvinkel, P.; Qureshi, A.R.; Lindholm, B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol. Dial. Transplant., 2003, 18, 590-7.
19. Menon, V.; Greene, T.; Wang, X.; Pereira, A.A.; Marcovina, S.M.; Beck, G.J.; Kusek, J.W.; Collins, A.J.; Levey, A.S.; Sarnak, M.J. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int., 2005, 68, 766-72.
20. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med., 1999, 130, 461-70.
21. Friedman, A.N.; Hunsicker, L.G.; Selhub, J.; Bostom, A.G; Collaborative Study Group. C-reactive protein as a predictor of total atherosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int., 2005, 68, 773-8.
22. Weiner, D.E.; Tighiouart, H.; Elsayed, E.F.; Griffith, J.L.; Salem, D.N.; Levey, A.S.; Sarnak, M.J. The relationship between non-traditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am. J. Kidney Dis, 2008, 51, 212-23.
23. Lacson, E.; Levin, N.W. C-Reactive Protein and End-Stage Renal Disease. Semin. Dial., 2004, 17, 438-48.
24. Korevaar, J.C.; Van Manen, J.G.; Dekker, F.W.; de Waart, D.R.; Boeschoten, E.W.; Kriediet, R for the NECOSAD STUDY GROUP. Effect of an increase in C - reactive protein level during a Hemodialysis session on mortality. J. Am. Soc. Nephrol., 2004, 15, 2916-22.
25. Wanner, C.; Zimmermann, J.; Schwedler, S.; Metzger, T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int., 2002, 61, 99-102.
26. Wang, A.Y.; Lam, C.W.; Wang, M.; Chan, I.H.; Yu, C.M.; Lui, S.F.; Sanderson, J.E. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study. Am. J. Nephrol., 2008, 28(4), 647-53.
27. Ducloux, D.; Bresson-Vautrin, C.; Kribs, M.; Aboudakr, A.; Chalopin, J.M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002, 62, 1417-22.
28. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr. Atheroscler. Rep. 2006, 8, 421-8.
29. Shlipak, M.G.; Fried, L.F.; Cushman, M.; Manolio, T.A.; Peterson, D.; Stehman-Breen, C.; Bleyer, A.; Newman, A.; Siscovick, D.; Psaty, B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA, 2005, 293, 1737-45.
30. Zoccali, C.; Mallamaci, F.; Tripepi, G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol. Dial. Transplant., 2004, 19(Suppl 5), 67-72.
31. Stenvinkel, P.; Barany, P.; Heimburger, O.; Pecoits-Filho, R.; Lindholm, B. Mortality, malnutrition and inflammation in ESRD: What is the role of interleukin-6? Kidney Int., 2002, 61(Suppl 80), S103-S108.
32. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation, 2000, 101, 1767-72.
33. Rao, M.; Guo, D.; Perianayagam, M.C.; Tighiouart, M.S.; Jaber, B.L.; Pereira, B.J.G; and the HEMO Study Group. Plasma Interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis., 2005, 45, 324-33.
34. Panichi, V.; Maggiore, U.; Taccola, D.; Migliori, M.; Rizza, G.M.; Consani, C.; Bertini, A.; Sposini, S.; Perez-Garcia, R.; Rindi, P.; Palla, R.; Tetta, C. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol. Dial. Transplant., 2004, 19, 1154-60.
35. Yudkin, J.S.; Kumari, M.; Humphries, S.E.; Mohamed-Ali, V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 2000, 148, 209-14.
36. Friedrich, B.; Alexander, D.; Janessa, A.; Häring, H.U.; Lang, F.; Risler, T. Acute effects of hemodialysis on cytokine transcription profiles: Evidence for C-reactive protein-dependency of mediator induction. Kidney Int., 2006, 70, 2124-30.
37. Tripepi, G.; Mallamaci, F.; Zoccali, C. Inflammation markers, adhesion molecules and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J. Am. Soc. Nephrol., 2005, 16, 83-8.
38. Honda, H.; Qureshi, A.R.; Heimburger, O.; Barany, P.; Wang, K.; Pecoits-Filho, R.; Stenvinkel, P.; Lindholm, B. Serum albumin, Creactive protein, interleukin-6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am. J. Kidney Dis., 2006, 47, 139-48.
39. Cybulsky, M.I.; Iiyama, K.; Li, H.; Zhu, S.; Chen, M.; Iiyama, M.; Davis, V.; Gutierrez-Ramos, J.C.; Connelly, P.W.; Milstone, D.S. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest., 2001, 107, 1255-62.
40. Dong, Z.M.; Brown, A.A.; Wagner, D.D. Prominent role of Pselectin in the development of advanced atherosclerosis in Apo-Edeficient mice. Circulation, 2000, 101, 2290-5.
41. Patel, S.S.; Thiagarajan, R.; Willerson, J.T.; Yeh, E.T. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in Apo-E-deficient mice. Circulation, 1999, 97, 75-81.
42. Stenvinkel, P.; Lindholm, B.; Heimburger, M.; Heimburger, O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: Association with malnutrition, inflammation and cardiovascular disease. Nephrol. Dial. Transplant., 2000, 15, 1624-30.
43. Papayianni, A.; Alexopoulos, E.; Giamalis, P.; Gionanlis, L.; Belechri, A.M.; Koukoudis, P.; Memmos, D. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol. Dial. Transplant., 2002, 17, 435-41.
44. Stenvinkel, P.; Carrero, J.J.; Axelsson, J.; Lindholm, B.; Heimburger, O.; Massy, Z. Emerging biomarkers for evaluating cardiovascular risk in chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin. J. Am. Soc. Nephrol., 2008, 3, 505-21.
45. Weissinger, E.M.; Kaiser, T.; Meert, N.; De Smet, R.; Walden, M.; Mischak, H.; Vanholder, R.C. Proteomics: A novel tool to unravel the pathophysiology of uraemia. Nephrol. Dial. Transplant., 2004, 19, 3068-77.
46. Weissinger, E.M.; Nguyen-Khoa, T.; Fumeron, C.; Saltiel, C.; Walden, M.; Kaiser, T.; Mischak, H.; Drueke, T.B.; Lacour, B.; Massy, Z.A. Effects of oral vitamin C supplementation in haemodialysis patients: A proteomic assessment. Proteomics, 2006, 6, 993-1000.
47. Stenvinkel, P.; Karimi, M.; Johansson, S.; Axelsson, J.; Suliman, M.; Lindholm, B.; Heimburger, O.; Barany, P.; Alvestrand, A.; Nordfors, L.; Qureshi, A.R.; Erkstrom, T.J.; Schalling, M. Impact of inflammation on epigenetic DNA methylation: a novel risk factor for cardiovascular disease? J. Int. Med., 2007, 261, 488-99.
48. Ingrosso, D.; Cimmino, A.; Perna, A.F.; Masella, L.; de Santo, N.G.; De Bonis, M.L.; Vacca, M.; Desposito, M.; Durso, M.; Galleti, P.; Zappia, V. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinemia in patients with uremia. Lancet, 2003, 361, 1693-9.
49. Stenvinkel, P.; Karimi, M.; Johansson, S.; Axelsson, J.; Suliman, M.; Lindholm, B.; Heimburger, O.; Barany, P.; Alvestrand, A.; Nordfors, L.; Qureshi, A.R.; Ekstrom, T.J.; Schalling, M. Impact of inflammation on epigenetic DNA methylation: A novel risk factor for cardiovascular disease? J Int Med, 2007, 261, 488-99.
50. Jofre, R.; Rodriguez-Benitez, P.; Lopez-Gomez, JM.; Perez-Garcia, R. Inflammatory syndrome in patients on hemodialysis. J. Am. Soc. Nephrol., 2006, 17, 274-80.
51. Guarnieri, G.; Biolo, G.; Zanetti, M.; Borazzoni, R. Chronic systemic inflammation in uremia: potential therapeutic approaches. Semin. Nephrol., 2004, 24, 441-5.
52. Lim, W.H.; Kireta, S.; Russ, E.R.; Russ, G.R.; Coates, P.T. Uremia impairs blood dendritic cell function in hemodialysis patients. Kidney Int., 2007, 71, 1122-31.
53. Schindler, R. Causes and therapy of microinflammation in renal failure. Nephrol. Dial. Transplant., 2004, 19, 34-40.
54. Poole, S.; Berd, T.A.; Selkirk, S.; Gaines-Das, R.E.; Choudry, Y.; Stephenson, S.L.; Kenny, A.J.; Saklatvaa, J. Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine, 1990, 2, 416-22.
55. Jacobs, P.; Glorieux, G.; Vanholder, R. Interleukin/cytokine profiles in hemodialysis and in continuous peritoneal dialysis. Nephrol. Dial. Transplant., 2004, 19 (Suppl 5), 41-5.
56. Glorieux, G.; Dhondt, A.; Jacobs, P.; Van Langeraert, J.; Lameire, N.H.; De Deyn, P.P.; Vanholder, R.C. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int., 2004, 65, 2184-92.
57. Vanholder, R.; De Smet, R.; Lameire, N. Protein-bound uremic solutes: the forgotten toxins. Kidney Int., 2001, 59(Suppl 78), S182-S185.
58. Boenisch, O.; William, C.; Koehne, P.; Wilde, A.; Frei, U.; Schindler, R. Acidosis induces and augments gene expression and synthesis of interleukin 6 and RANTES in smooth muscle cells[abstract]. J. Am. Soc. Nephrol., 2001, 12, 133A.
59. Niebauer, J.; Volk, H.D.; Kemp, M.; Dominguez, M.; Schumann, R.R.; Rauchhaus, M.; Poole-Wilson, P.A.; Coats, A.J.; Anker, S.D. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, 1999, 353, 1838-42.
60. Dumler, F. Hypoalbuminemia is a marker of overhydration in chronic maintenance patients on dialysis. ASAIO J., 2003, 49, 282-6.
61. Torre Amiore, G.; Kapadia, S.; Lee, J.; Durand, J.B.; Bies, R.D.; Young, J.B.; Mann, D.L. Tumor necrosis factor alpha and tumor necrosis factors receptors in the failing human heart. Circulation, 1996, 93, 704-11.
62. Murray, D.R.; Prabhu, S.D.; Chandrasekar, B. Chronic betaadrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation, 2000, 101, 2338-41.
63. Ohtsuka, T.; Hamada, M.; Hiasa, G.; Sasaki, O.; Suzuki, M.; Hara, Y.; Shigematsu, Y.; Hiwada, K. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol., 2001, 37, 412-7.
64. Losito, A.; Kalidas, K.; Santoni, S.; Jeffery, S. Association of interleukin-6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int., 2003, 64, 616-22
65. Park, C.W.; Shin, Y.S.; Kim, K.M.; Lee, S.Y.; Yu, S.E.; Kim, S.Y.; Choi, E.J.; Chang, Y.S.; Bang, B.K. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am. J. Kidney Dis., 2002, 40, 1230-9.
66. Filiopoulos, V.; Hadjiyannakos, D.; Metaxaki, P.; Sideris, V.; Takouli, L.; Anogiati, A.; Vlassopoulos, D. Inflammation and oxidative stress in patients on hemodiafiltration. Am. J. Nephrol., 2008, 28(6), 949-67.
67. Himmelfarb, J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin. Dial., 2004, 17, 449-54.
68. Senol, E.; Ersoy, A.; Erdinc, S.; Sarandol, E.; Yurtkuran, M. Oxidative stress and ferritin levels in haemodialysis patients. Nephrol. Dial. Transplant., 2008, 23, 665-72.
69. Ketteler, M.; Giachelli, C. Novel insights into vascular calcification. Kidney Int., 2006, 70, S5-S9.
70. Cozzolino, M.; Brancaccio, D.; Gallieni, M.; Slatopolsky, E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int., 2005, 68, 429-36.
71. Goldsmith, D.; Ritz, E.; Covic, A. Vascular calcification: a stiff challenge for the nephrologists. Kidney Int., 2004, 66, 1315-33.
72. Rogers, N.M.; Teubner, D.J.; Coates, P.T. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin. Dial., 2007, 20, 150-7.
73. Choudhury, D.; Luna-Salazar, S. Preventive health care in chronic kidney disease and end-stage renal disease. Nat. Clin. Pract. Nephrol. 2008, 4, 194-206.
74. Zoccali, C.; Mallamaci, F.; Tripepi, G. Atherosclerosis in dialysis patients: Does Chlamydia pneumoniae infection contribute to cardiovascular damage? Nephrol. Dial. Transplant., 2002, 17(Suppl 8), 25-8.
75. Kato, A.; Takita, T.; Maruyama, Y.; Hishida, A. Chlamydial infection and progression of carotid atherosclerosis in patients on regular hemodialysis. Nephrol. Dial. Transplant., 2004, 19, 2539-46
76. Tsirpanlis, G.; Chatzipanagiotou, S.; Ioannidis, A.; Moutafis, S.; Poulopoulou, C.; Nicolaou, C. Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells: correlation with inflammation and atherosclerosis in hemodialysis patient. Nephrol. Dial. Transplant., 2003, 18, 918-23.
77. Lentine, K.L.; Parsonnet, J.; Taylor, I.; Wrone, E.M.; Lafayette, R.A. Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients. Clin. Exp. Nephrol., 2006, 10, 55-62.
78. Borawski, J.; Wilczynska-Borawska, M.; Stokowska, W.; Mysliwiec, M. The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients. Nephrol. Dial. Transplant., 2007, 22, 457-64.
79. Chen, L.P.; Chiang, C.K.; Chan, C.P.; Hung, K.Y.; Huang, C.S. Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? Am. J. Kidney Dis., 2006, 47, 815-22.
80. Rahmati, M.A.; Craig, R.G.; Homel, P.; Kaysen, G.A.; Levin, N.W. Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am. J. Kidney Dis. 2002, 40, 983-9.
81. Kadiroglu, A.K.; Kadiroglu, E.T.; Sit, D.; Dag, A.; Yilmaz, M.E. Periodontitis is an important and occult source of inflammation in hemodialysis patients. Blood Purif., 2006, 24, 400-4.
82. Hussein, M.M.; Mooij, J.M.; Roujouleh, H. Tuberculosis and chronic renal disease. Semin. Dial., 2003, 16, 38-44.
83. Pastan, S.; Soucie, J.M.; McClellan, W.M. Vascular access and increased risk of death among hemodialysis patients. Kidney Int., 2002, 62, 620-6.
84. Chang, C.J.; Ko, Y.S.; Ko, P.J.; Hsu, L.A.; Chen, C.F.; Yang, C.W.; Hsu, T.S.; Pang, J.H. Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int., 2005, 68, 1312-9.
85. Nassar, G.M.; Fishbane, S.; Ayus, J.C. Occult infection of old nonfunctioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int., 2002, 80, 49-54.
86. Fortes, P.C.; Versari, P.H.; Stinghen, A.E.M.; Pecoits-Filho, R. Controlling inflammation in peritoneal dialysis: the role of PDrelated factors as potential intervention targets. Perit. Dial. Int., 2007, 27(Suppl 2), S76-S81.
87. Kotanko, P.; Carter, M.; Levin, N.W. Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol. Dial. Transplant., 2006, 21, 2057-60.
88. Simenhoff, M.L.; Saukkonen, J.J.; Burke, J.F.; Wesson, L.G., Jr.; Schaedler, R.W.; Gordon, S.J. Bacterial populations of the small intestine in uremia. Nephron, 1978, 22, 63-8.
89. Bammens, B.; Evenepoel, P.; Keuleers, H.; Verbeke, K.; Vanrenterghem, Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int., 2006, 69, 1081-7.
90. De Almeida Duarte, J.B.; de Aguilar-Nascimento, J.E.; Nascimento, M.; Nochi, R.J., Jr. Bacterial translocation in experimental uremia. Urol. Res., 2004, 32, 266-70.
91. Wandersman, C.; Delepelaire, P. Bacterial iron sources: from siderophores to hemophores. Annu. Rev. Microbiol., 2004, 58, 611-47.
92. Stenvinkel, P.; Pecoits-Filho, R.; Lindholm, B.; for the DialGene Consortium. Gene polymorphism association studies in dialysis: The nutrition-inflammation axis. Semin. Dial., 2005, 18, 322-30.
93. Lopez-Gomez, JM.; Perez-Flores, I.; Jofre, R.; Carratero, D.; Rodriguez-Benitez, P.; Villaverde, M.; Perez-Garcia, R.; Nassar, GM.; Niembro, E.; Ayus, J.C. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J. Am. Soc. Nephrol., 2004, 15, 2494-501.
94. Ramos, L.F.; Shintani, A.; Ikizler, A.; Himmelfarb, J. Oxidative Stress and Inflammation are associated with adiposity in moderate to severe CKD. J. Am. Soc. Nephrol., 2008, 19, 593-9.
95. Ramkumar, N.; Cheung, A.K.; Pappas, L.M.; Roberts, W.L.; Beddhu, S. Association of obesity with inflammation in chronic kidney disease: an observational study. J. Ren. Nutr., 2004, 14, 201-7.
96. Menon, V.; Wang, X.; Greene, T.; Beck, G.L.; Kusek, J.W.; Marcovina, S.M.; Levey, A.S.; Sarnak, M.J. Relationship between C-reactive protein, albumin and cardiovascular disease in patients with chronic kidney disease. Am. J. Kidney Dis. 2003, 42, 44-52.
97. Wellen, K.E.; Hotamisligil, G.S. Obesity-induced inflammatory changes in adipose tissues. J. Clin. Invest., 2003, 112, 1785-8.
98. Shibata, R.; Ouchi, N.; Murohara T. Adiponectin and cardiovascular disease. Circ. J., 2009, 73, 608-14.
99. Kopple, J.D. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am. J. Clin. Nutr., 2006, 83, 202-10.
100. Tayeb, J.S.; Provenzano, R.; El Ghoroury, M.; Bollovich, K.; Khairullah, Q.; Pieper, D.; Morrison, L.; Calleja, Y. Effect of biocompatibility on serum albumin levels. Am. J. Kidney Dis., 2000, 35, 606-10.
101. Memoli, B.; Minutolo, R.; Bisesti, V.; Postiglione, L.; Conti, A.; Marzano, L.; Capuano, A.; Andreucci, M.; Baletto, M.M.; Guida, B.; Tetta, C. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am. J. Kidney Dis., 2002, 39, 266-73.
102. Schindler, R.; Boenisch, O.; Fischer, C.; Frei, U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin. Nephrol., 2000, 53, 452-9.
103. Panichi, V.; Manca-Rizza, G.; Paoletti, S.; Taccola, D.; Consani, C.; Filippi, C.; Mantuano, E.; Sidoti, A.; Grazi, G.; Antonelli, A.; Angelini, D.; Petrone, I.; Mura, C.; Tolaini, P.; Saloi, F.; Ghezzi, PM.; Barsotti, G.; Palla, R. Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs online haemodiafiltration: a cross-over randomized multicentre trial. Nephrol. Dial. Transplant., 2006, 21, 756-62.
104. Calo, A.C.; Naso, A.; Carraro, G.; Wratten, M.L.; Pagnin, E.; Bertipaglia, L.; Rebeschini, M.; Davis, P.A.; Piccoli, A.; Cascone, C. Effect of hemodiafiltration with on-line regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol. Dial. Transplant., 2007, 22, 1413-9.
105. Ayus, J.C.; Mizani, M.R.; Achinger, S.G.; Thadhani, R.; Go, A.S.; Lee, S. Effects of Short Daily versus Conventional Hemodialysis on Left Ventricular Hypertrophy and Inflammatory Markers: A Prospective, Controlled Study. J. Am. Soc. Nephrol., 2005, 16, 2778-88.
106. Schindler, R.; Beck, W.; Deppish, R.; Aussieker, M.; Wilde, A.; Göhl, H.; Frei, U. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J. Am. Soc. Nephrol., 2004, 15, 3207-14.
107. Pereira, B.J.; Snodgrass, B.R.; Hogan, P.J.; King, A.J. Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. Kidney Int., 1995, 47, 603-10.
108. Schindler, R.; Christ-Kohlrausch, F.; Frei, U.; Shaldon, S. Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. Clin. Nephrol., 2003, 59, 447-54.
109. Amore, A.; Cirina, P.; Bonaudo, R.; Conti, C.; Chiesa, M.; Coppo, R. Bicarbonate dialysis, unlike acetate-free biofiltration, triggers mediators of inflammations and apoptosis in endothelial and smooth muscle cells. J. Nephrol., 2006, 19, 57-64.
110. Lim, P.S.; Wei, Y.H.; Yu, Y.L.; Kho, B. Enhanced oxidative stress in hemodialysis patients receiving intravenous iron therapy. Nephrol. Dial. Transplant., 1999, 14, 2680-7.
111. De Vecchi, A.F.; Novembrino, C.; Lonati, S.; Ippolito, S.; Bamonti, F. Two different modalities of iron gluconate i.v. administration: effects on iron oxidative and inflammatory status in peritoneal dialysis patients. Nephrol. Dial. Transplant., 2007, 22, 1709-13.
112. Pecoits-Filho, R.; Stenvinkel, P.; Wang, A.Y.; Heimbürger, O.; Lindholm, B. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit. Dial. Int., 2006, 24, 327-39.
113. Stenvinkel, P.; Heimbürger, O.; Lindholm, B.; Kaysen, G.A.; Bergström, J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transplant., 2000, 15, 953-60.
114. Fouque, D.; Kalantar-Zadeh, K.; Kopple, J.; Cano, N.; Chauveau, P.; Cuppari, L.; Franch, H.; Guarnieri, G.; Ikizler, T.A.; Kaysen, G.; Lindholm, B.; Massy, Z.; Mitch, W.; Pineda, E.; Stenvinkel, P.; Treviño-Becerra, A.; Wanner, C. A proposed nomenclature and diagnostic criteria for energy-protein wasting in acute and chronic kidney disease. Kidney Int., 2008, 73, 391-8.
115. de Mutsert, R.; Grootendorst, D.C.; Axelsson, J.; Boeschoten, E.W.; Krediet, R.T.; Dekker, FW.; and the NECOSAD Study Group. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol. Dial. Transplant., 2008, 23, 2957-64.
116. Kaysen, G.A. Inflammation: Cause of vascular disease and malnutrition in dialysis patients. Semin. Nephrol., 2004, 24, 431-6.
117. Wish, J.B. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol., 2006, 1, 4-8.
118. Yu, T.M.; Chen, Y.H.; Hsu, J.Y.; Sun, C.S.; Chuang, Y.W.; Chen, C.H.; Wu, M.J.; Cheng, C.H.; Shu, K.H. Systemic inflammation is associated with pulmonary hypertension in patients undergoing hemodialysis. Nephrol. Dial. Transplant., 2009, 24, 1946-51.